Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia

Urologia Internationalis

Volumn 80, Issue 1, 2008, Pages 68-73

  Sciarra, Alessandro ^a   Gentile, Vincenzo ^a   Monti, Salvatori ^a   Dattilo, Cristian ^a   Autran Gomez, Anna ^a   Salciccia, Stefano ^a   Proietti Pannunzi, Laura ^a   Toscano, Vincenzo ^b   Di Silverio, Franco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chromogranin A; Insulin like growth factor; Prostate neoplasm; Prostate specific antigen; Serum marker

Indexed keywords

CHROMOGRANIN A; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER STAGING; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; PROSTATE HYPERTROPHY; PROSTATECTOMY; RADIOIMMUNOASSAY; STATISTICAL ANALYSIS;

ADENOCARCINOMA; AGED; CHROMOGRANIN A; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REFERENCE VALUES; TUMOR MARKERS, BIOLOGICAL;

EID: 38349189488     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111733     Document Type: Article

References (18)

1. Sciarra A, Voria G, Monti S, Mazzone L, Mariotti G, Pozza M, D'Eramo G, Di Silverio F: Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A. Prostate 2004;58:421-428.
2. Di Sant'Agnese I, Cickett AT: Neuroendocrine differentiation in prostatic malignancy. Cancer 1996;78:357-361.
3. Abrahamsson PA: Neuroendocrine differentiation in prostate carcinoma. Prostate 1999;39:135-148.
4. Deftos LJ, Abrahamsson PA: Granins and prostate cancer. Urology 1998;51(suppl 5A):141-145.
5. Cussenot O, Villette JM, Cochand-Priollet B, Berthon P: Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors. Prostate 1998;8(suppl):43-51.
6. Kimura N, Hoshi S, Takahaski M, Takeha S, Shizawa S, Nagura H: Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. J Urol 1997;157:565-568.
7. Berruti A, Dogliotti L, Mosca A, Bellina M, Mari M, Torta M, Tarabuzzi R, Bollito E, Fontana D, Angeli A: Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000;88:2590-2597.
8. Fuerstenberger G, Senn HJ: Insulin-like growth factors and cancer. Lancet Oncol 2002;3:298-302.
9. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM: The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate model. Cancer Res 1999;59:2203-2209.
10. Jerome L, Shiry L, Leyland-Jones B: Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer 2003;10:561-578.
11. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M: Insulin-like growth factor 1 and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-1106.
12. Djavan B, Bursa B, Seitz C, Soeregi G, Remzi M, Basharkhah A: Insulin-like growth factor 1, IGF-1 density and IGF-1/PSA ratio for prostate cancer detection. Urology 1999;54:603-606.
13. Marszalek M, Watcher J, Ponholzer A, Leitha T, Rauchenwald M, Madersbacher S: Insulin-like growth factor 1, chromogranin A and prostate-specific antigen serum levels in prostate cancer patients and controls. Eur Urol 2005;48:34-39.
14. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO: Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997;76:1115-1118.
15. Cutting CW, Hunt C, Bland JM, Dalgleish AG, Kirby RS: Serum insulin-like growth factor 1 is not a useful marker of prostate cancer. BJU Int 1999;83:996-999.
16. Inne P, Auvunen A, Kositinen H, Zhang WM, Maattanen L, Rannikko S: Insulin-like growth factor 1 is not useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab 2000;85:2744-2747.
17. Ismail HA, Pollak M, Behlouli H, Tanguay S, Begin LR, Aprikian AG: Serum insulin-like growth factor (IGF)-1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples. BJU Int 2003;92:699-702.
18. Sciarra A, Mariotti G, Gentile V, Voria G, Monti S, Di Silverio F: Neuroendocrine differentiation in human prostate tissue: Is it detectable and treatable? BJU Int 2003;91:438-445.